Literature DB >> 27814957

How much liver needs to be transected in ALPPS? A translational study investigating the concept of less invasiveness.

Michael Linecker1, Patryk Kambakamba1, Cäcilia S Reiner2, Thi Dan Linh Nguyen-Kim2, Gregor A Stavrou3, Robert M Jenner4, Karl J Oldhafer3, Bergthor Björnsson5, Andrea Schlegel1, Georg Györi1, Marcel André Schneider1, Mickael Lesurtel6, Pierre-Alain Clavien1, Henrik Petrowsky7.   

Abstract

BACKGROUND: ALPPS induces rapid liver hypertrophy after stage-1 operation, enabling safe, extended resections (stage-2) after a short period. Recent studies have suggested that partial transection at stage-1 might be associated with a better safety profile. The aim of this study was to assess the amount of liver parenchyma that needs to be divided to achieve sufficient liver hypertrophy in ALPPS.
METHODS: In a bi-institutional, prospective cohort study, nonfibrotic patients who underwent ALPPS with complete (n = 22) or partial (n = 23) transection for colorectal liver metastases were analyzed and compared with an external ALPPS cohort (n = 23). A radiologic tool was developed to quantify the amount of parenchymal transection. Liver hypertrophy and clinical outcome were compared between both techniques. The relationship of partial transection and hypertrophy was investigated further in an experimental murine model of partial ALPPS. RESULT: The median amount of parenchymal transection in partial ALPPS was 61% (range, 34-86%). The radiologic method correlated poorly with the intraoperative surgeon's estimation (rS = 0.258). Liver hypertrophy was equivalent for the partial ALPPS, ALPPS, and external ALPPS cohort (64% vs 60% vs. 64%). Experimental data demonstrated that partial transection of at least 50% induced comparable hypertrophy (137% vs 156%) and hepatocyte proliferation compared to complete transection.
CONCLUSION: The study provides clinical and experimental evidence that partial liver partition of at least 50% seems to be equally effective in triggering volume hypertrophy as observed with complete transection and can be re recommended as less invasive alternative to ALPPS.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27814957     DOI: 10.1016/j.surg.2016.08.004

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

Review 1.  Modified ALPPS procedures: more safety through less invasive surgery.

Authors:  Kuniya Tanaka
Journal:  Langenbecks Arch Surg       Date:  2017-05-10       Impact factor: 3.445

Review 2.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

Review 3.  Associated liver partition and portal vein ligation for staged hepatectomy: a review.

Authors:  Kai Siang Chan; Jee Keem Low; Vishal G Shelat
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

4.  Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score: is the patient suitable for Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)?

Authors:  Ivan Capobianco; Karl J Oldhafer; Mohammed-Hossein Fard-Aghaie; Ricardo Robles-Campos; Roberto Brusadin; Henrik Petrowsky; Michael Linecker; Arianeb Mehrabi; Katrin Hoffmann; Jun Li; Asmus Heumann; Roberto Hernandez-Alejandro; Mauro Enrique Tun-Abraham; Elio Jovine; Matteo Serenari; Bergthor Bjornsson; Per Sandström; Ruslan Alikhanov; Mikhail Efanov; Paolo Muiesan; Andrea Schlegel; Thomas M van Gulik; Pim B Olthof; Gregor Alexander Stavrou; Lina Maria Serna-Higuita; Alfred Königsrainer; Silvio Nadalin
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

5.  How should liver hypertrophy be stimulated? A comparison of upfront associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE) with rescue possibility.

Authors:  Ernesto Sparrelid; Kristina Hasselgren; Bård Ingvald Røsok; Peter Nørgaard Larsen; Nicolai Aagaard Schultz; Ulrik Carling; Eva Fallentin; Stefan Gilg; Per Sandström; Gert Lindell; Bergthor Björnsson
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 7.293

6.  MMP2/9 downregulation is responsible for hepatic function recovery in cirrhotic rats following associating liver partition and portal vein ligation for staged hepatectomy.

Authors:  Yugang Qin; Chonghui Li; Xinlan Ge; Qiang Zhang; Xiaojun Wei; Rong Liu
Journal:  Ann Transl Med       Date:  2022-04

7.  Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines.

Authors:  Giulia Manzini; Doris Henne-Bruns; Franz Porzsolt; Michael Kremer
Journal:  BMJ Open Gastroenterol       Date:  2017-03-24

Review 8.  A Comparison of Pitfalls after ALPPS Stage 1 or Portal Vein Embolization in Small-for-Size Setting Hepatectomies.

Authors:  Andreas A Schnitzbauer
Journal:  Visc Med       Date:  2017-12-04

9.  Did the International ALPPS Meeting 2015 Have an Impact on Daily Practice? The Hamburg Barmbek Experience of 58 Cases.

Authors:  Gregor A Stavrou; Marcello Donati; Mohammad H Fard-Aghaie; Martin Zeile; Tessa M Huber; Axel Stang; Karl J Oldhafer
Journal:  Visc Med       Date:  2017-11-30

10.  ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial).

Authors:  Per Sandström; Bård I Røsok; Ernesto Sparrelid; Peter N Larsen; Anna L Larsson; Gert Lindell; Nicolai A Schultz; Bjorn A Bjørnbeth; Bengt Isaksson; Magnus Rizell; Bergthor Björnsson
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.